Increased miR-142 and decreased DJ-1 enhance the sensitivity of pancreatic cancer cell to adriamycin
Authors: G-Y Han
J-H Cui
S Liang
H-L Li
Journal: European review for medical and pharmacological sciences (2018)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: PI3K/AKT signaling pathway; DJ-1; PTEN; MiR-142; survivin
Affiliations: Second Department of General Surgery, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, China. .

Abstract:  Objective: Phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) signaling pathway is related to tumorigenesis by up-regulating survivin. Phosphatase and tensin homologue deleted on chromosome ten (PTEN) can suppress PI3K/AKT signaling pathway, while DJ-1 is the negative regulator of PTEN. DJ-1 up-regulation is closely correlated with the occurrence, progression, and drug resistance of pancreatic cancer. MicroRNA-142 (MiR-142) is significantly declined in pancreatic cancer tissue. Bioinformatics analysis demonstrated that complementary binding site exists between miR-142 and DJ-1. This investigation, therefore, aimed to study the role of miR-142 in the regulation of DJ-1-PTEN/PI3K/AKT/Survivin signaling pathway as well as in pancreatic cancer cell proliferation, apoptosis, and adriamycin (ADM) resistance. Materials and methods: Dual luciferase assay was performed to assess the targeted relationship between miR-142 and DJ-1. MiR-142, DJ-1, and PTEN expressions in SW1990 cells and drug-resistant SW1990/ADM cells were compared. SW1990/ADM cells were divided into five groups, including mimic-NC, miR-142 mimic, small interfere normal control (si-NC), si-DJ-1, and miR-142 mimic + si-DJ-1 groups. DJ-1, PTEN, phosphorylated-AKT (p-AKT), and Survivin expressions were tested. Cell apoptosis was determined by flow cytometry. Cell proliferation was evaluated by EdU staining. Results: MiR-142 targeted inhibited DJ-1 expression. MiR-142, PTEN, and cell apoptosis significantly down-regulated, while DJ-1, p-AKT, Survivin, and cell proliferation significantly elevated in SW1990/ADM cells compared with SW1990 cells. MiR-142 mimics and/or si-DJ-1 transfection markedly reduced DJ-1, p-AKT, and Survivin expressions enhanced PTEN level, attenuated cell proliferation, enhanced cell apoptosis, and weakened ADM resistance. Conclusions: MiR-142 over-expression weakened ADM resistance in pancreatic cancer cells by targeting DJ-1 to enhance PTEN expression and attenuate PI3K/AKT signaling pathway activity. 

Retracted: Yes

PubPeer comments:
 A Gallery of Unfortunate FACS Plots. Please excuse the length. This is a random assortment from a certain oeuvre. Any other of ~40 papers from the same journal(s) could have been used instead. I have only marked a few of the recurring constellations of points. Colored plots darkened and contrast-enhanced for visibility. Fig 4C [Liu et al (2017)] PMID 28770966 Fig 2D, 3D [Wu et al (2017)] PMID 28617558 Fig 2D [Liang et al (2017)] PMID 29164556  Fig 3E [Li et al (2018)] 10.26355 eurrev_201809_15933 Fig 4D [Dong et al (2018)] 10.26355 eurrev_201805_15059 Fig 4D [Song et al (2018)] 10.26355 eurrev_201806_15153  Fig 2B, 4B, 5C [Wang et al (2018)] 10.26355 eurrev_201801_14201 Fig 3B, 4E [Su Song (2018)] 10.26355 eurrev_201810_16155 Fig 2D [Han et al (2018)] 10.26355 eurrev_201811_16390  Fig 4C [Wang Yu (2019)] 10.26355 eurrev_201903_17397 Fig 5D [Zhou et al (2019)] 10.26355 eurrev_201911_19436 Fig 4E [Liu Zhang (2019)] 10.1089 cbr.2018.2749 Fig 4D [Piao et al (2019)] 10.1089 cbr.2018.2625  , 
 It may also be worth documenting the curious stylized renditions of Western Blots favoured by this production studio (and by the editors and reviewers who accept this oeuvre of papers).  , 
 Withdrawn. https: www.europeanreview.org article 23751 *Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, u201cIncreased miR-142 and decreased DJ-1 enhance the sensitivity of pancreatic cancer cell to adriamycin, by G.-Y. Han, J.-H. Cui, S. Liang, H.-L. Li, published in Eur Rev Med Pharmacol Sci 2018; 22 (22): 7696-7703u2013DOI: 10.26355 eurrev_201811_16390u2013PMID: 30536312u201d has been withdrawn.* *The Publisher apologizes for any inconvenience this may cause.* ,